NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.15−0.40 (-15.69%)
Close on Nov 20, 2026Market cap $93.09MP/E –Yield –
NRX Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
NRX Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2025 was -$11.91M. For fiscal 2024 it was -$10.64M. The highest annual figure on record is -$2.27M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$10.64M | – |
| FY2023 | Dec 31, 2023 | -$21.66M | – |
| FY2022 | Dec 31, 2022 | -$39.77M | – |
| FY2021 | Dec 31, 2021 | -$37.71M | – |
| FY2020 | Dec 31, 2020 | -$2.27M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -$4.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.48M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.10M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.32M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.27M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.38M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.02M | – |
See a number that looks wrong?